TrialBritish journal of clinical pharmacology2013

Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers.

S Aubrey Stoch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.